| Index | S&P 500 | P/E | — | EPS (ttm) | -0.36 | Insider Own | 0.53% | Shs Outstand | 1.15B | Perf Week | 5.78% |
| Market Cap | 21.87B | Forward P/E | 7.00 | EPS next Y | 2.72 | Insider Trans | -0.83% | Shs Float | 1.14B | Perf Month | 9.05% |
| Enterprise Value | 33.87B | PEG | — | EPS next Q | 0.64 | Short Float | 3.32% | Perf Quarter | 8.00% | ||
| Income | -411.00M | P/S | 1.48 | EPS this Y | 8.65% | Short Ratio | 4.10 | Perf Half Y | 26.60% | ||
| Sales | 14.74B | P/B | 1.53 | EPS next Y | 7.99% | ROA | -1.17% | Short Interest | 37.93M | Perf YTD | 52.93% |
| Book/sh | 12.42 | P/C | 14.47 | EPS next 5Y | 5.09% | ROE | -2.79% | 52W High | 19.51 -2.41% | Perf Year | 85.39% |
| Cash/sh | 1.32 | P/FCF | 11.68 | EPS past 3/5Y | — | ROIC | -0.18% | 52W Low | 9.92 91.94% | Perf 3Y | 112.26% |
| Dividend Est. | 0.48 (2.52%) | EV/EBITDA | 12.47 | Sales past 3/5Y | -4.20% 3.66% | Gross Margin | 34.83% | Volatility | 2.40% 2.54% | Perf 5Y | 36.59% |
| Dividend TTM | 0.48 (2.52%) | EV/Sales | 2.30 | EPS Y/Y TTM | — | Oper. Margin | -0.59% | ATR (14) | 0.48 | Perf 10Y | -49.38% |
| Dividend Ex-Date | Aug 21, 2026 | Quick Ratio | 0.96 | Sales Y/Y TTM | 4.41% | Profit Margin | -2.79% | RSI (14) | 64.14 | Recom | 2.69 |
| Dividend Gr. 3/5Y | 0.00% — | Current Ratio | 1.58 | EPS Q/Q | 11.29% | SMA20 | 4.99% | Beta | 0.88 | Target Price | 21.00 |
| Payout | — | Debt/Eq | 0.95 | Sales Q/Q | 4.89% | SMA50 | 9.09% | Rel Volume | 0.96 | Prev Close | 19.20 |
| Employees | 30,000 | LT Debt/Eq | 0.83 | Earnings | Nov 05 | SMA200 | 19.78% | Avg Volume | 9.12M | Price | 19.04 |
| IPO Date | Mar 17, 1980 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 14.79% 2.21% | Net Debt/EBITDA | 4.42 | Volume | 8,784,895 | Change | -0.83% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-26-26 | Reiterated | Piper Sandler | Neutral | $12 → $14 |
| Oct-05-26 | Reiterated | UBS | Buy | $18 → $26 |
| Sep-23-26 | Initiated | Oppenheimer | Outperform | $25 |
| Sep-09-26 | Initiated | Leerink | Outperform | $20 |
| Sep-08-26 | Reiterated | Argus Research | Buy | $15 → $20 |
| May-19-26 | Reiterated | Barclays | Overweight | $15 → $22 |
| May-08-26 | Reiterated | Truist Securities | Buy | $16 → $20 |
| Feb-09-26 | Reiterated | UBS | Neutral | $12 → $18 |
| Jan-28-26 | Reiterated | Piper Sandler | Neutral | $13 → $12 |
| Jan-16-26 | Upgrade | Argus Research | Hold → Buy | $15 |
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 14,738 | 14,300 | 14,739 | 15,427 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 9,604 | 9,286 | 9,116 | 8,988 | — | — | — | — | — | |
| Gross Profit | 5,134 | 5,014 | 5,624 | 6,439 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 3,978 | 3,794 | 4,426 | 4,650 | — | — | — | — | — | |
| Research and Development | 1,022 | 966 | 809 | 805 | — | — | — | — | — | |
| Other Operating Expense | 220 | 2,917 | 379 | 217 | — | — | — | — | — | |
| Operating Income | -87 | -2,663 | 10 | 766 | — | — | — | — | — | |
| Interest Expense | 481 | 471 | 550 | 573 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -95 | -531 | -83 | 10 | — | — | — | — | — | |
| Net Income Before Taxes | -662 | -3,665 | -623 | 203 | — | — | — | — | — | |
| Income Taxes | -252 | -150 | 11 | 148 | — | — | — | — | — | |
| Consolidated Net Income | -411 | -3,515 | -634 | 55 | — | — | — | — | — | |
| Net Income From Continuing Operations | -411 | -3,515 | -634 | 55 | — | — | — | — | — | |
| Net Income | -411 | -3,515 | -634 | 55 | — | — | — | — | — | |
| EPS (Recurring) | -0.36 | -3.00 | -0.53 | 0.05 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.36 | -3.00 | -0.53 | 0.05 | — | — | — | — | — | |
| EPS (Diluted) | -0.36 | -3.00 | -0.53 | 0.05 | — | — | — | — | — | |
| EBITDA | 2,716 | -395 | 2,635 | 3,517 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | 239.07 | — | — | — | — | — | |
| Price To Sales Ratio | 1.50 | 1.02 | 1.01 | 0.84 | — | — | — | — | — | |
| Gross Margin | 34.84 | 35.06 | 38.16 | 41.74 | — | — | — | — | — | |
| Operating Margin | -0.59 | -18.62 | 0.07 | 4.97 | — | — | — | — | — | |
| Net Margin | -2.79 | -24.58 | -4.30 | 0.36 | — | — | — | — | — | |
| Shares Outstanding | 1,163 | 1,171 | 1,193 | 1,200 | — | — | — | — | — | |
| Market Capitalization | 22,144 | 14,579 | 14,853 | 12,996 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Enrietti Andrew | Officer | Aug 15 '26 | Option Exercise | 0.00 | 27,131 | 0 | 244,811 | Aug 18 |
| Campbell Paul | Officer | Jun 25 '26 | Sale | 16.17 | 50,076 | 809,784 | 316,212 | Jun 26 |
| Le Goff Corinne | Chief Commercial Officer | Apr 15 '26 | Option Exercise | 0.00 | 42,988 | 0 | 122,558 | Apr 16 |
| Campbell Paul | Officer | Mar 23 '26 | Sale | 13.28 | 21,350 | 283,539 | 366,288 | Mar 24 |
| SEVERINO MICHAEL | Director | Mar 06 '26 | Option Exercise | 0.00 | 26,949 | 0 | 26,031 | Mar 10 |
| Enrietti Andrew | Officer | Mar 06 '26 | Option Exercise | 0.00 | 20,121 | 0 | 227,477 | Mar 10 |
| PARRISH MARK W | Director | Mar 06 '26 | Option Exercise | 0.00 | 26,009 | 0 | 165,230 | Mar 10 |
| Campbell Paul | Officer | Mar 06 '26 | Option Exercise | 0.00 | 28,974 | 0 | 398,956 | Mar 10 |
| MARK RICHARD A | Director | Mar 06 '26 | Option Exercise | 0.00 | 26,009 | 0 | 116,145 | Mar 10 |
| Smith Scott Andrew | Chief Executive Officer | Mar 06 '26 | Option Exercise | 0.00 | 136,882 | 0 | 1,374,576 | Mar 10 |
| HIGGINS MELINA E | Director | Mar 06 '26 | Option Exercise | 0.00 | 26,009 | 0 | 146,048 | Mar 10 |
| Groothuis Leo Frans | Director | Mar 06 '26 | Option Exercise | 0.00 | 26,009 | 0 | 63,567 | Mar 10 |
| SIMMONS DAVID S | Director | Mar 06 '26 | Option Exercise | 0.00 | 23,867 | 0 | 23,344 | Mar 10 |
| Le Goff Corinne | Chief Commercial Officer | Mar 06 '26 | Option Exercise | 0.00 | 48,550 | 0 | 101,582 | Mar 10 |
| Mistras Theodora | Chief Financial Officer | Mar 06 '26 | Option Exercise | 0.00 | 43,782 | 0 | 92,787 | Mar 10 |